A Study in North Macedonia Investigating Retrospective Data of Glucagon-like Peptide-1 (GLP-1) Participants With Type 2 Diabetes (T2D) in Real World Environment (RWE) Setting (MIRAGE)

Sponsor
Novo Nordisk A/S
Study ID
NCT05468632
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide — DRUG
    Participants who initiated once weekly (OW) semaglutide in routine clinical practice in were enrolled in the study. The participants were treated according to current clinical practice, applicable local labels, and standard of care as per physicians' discretion.

Study Details

The purpose of this study is to investigate glycaemic control and other clinical parameters in glucagon like peptide -1 (GLP-1) naive adult participants with type 2 diabetes (T2D) who initiated once weekly (OW) semaglutide in local clinical practice in North Macedonia. The participants were treated according to current clinical practice, applicable local labels, and standard of care as per physicians' discretion. The total duration of the study is planned to be approximately 30 weeks which is the period from OW semaglutide initiation to end of follow up.

Key Dates

Start date
Jul 5, 2022
Status verified
Feb 2023
Primary completion
Jul 31, 2022
Completion
Jul 31, 2022

Study Design

Enrollment
314 participants (actual)

Arms

  • Arm: Glucagon like peptide-1 (GLP-1) naive participants with Type 2 Diabetes (T2D)
    Glucagon like peptide-1 (GLP-1) naive adult type 2 diabetes (T2D) participants who initiated once weekly (OW) semaglutide were treated according to current clinical practice, applicable local labels, and standard of care as per physicians' discretion.

Primary Outcome Measure

Change in glycated haemoglobin (HbA1c) [ Time Frame: From baseline (week 0) to end of follow-up (week 30+- 4 weeks) ]

Related Studies